IL123453A - Pharmaceutical preparation for use in dementia - Google Patents
Pharmaceutical preparation for use in dementiaInfo
- Publication number
- IL123453A IL123453A IL12345398A IL12345398A IL123453A IL 123453 A IL123453 A IL 123453A IL 12345398 A IL12345398 A IL 12345398A IL 12345398 A IL12345398 A IL 12345398A IL 123453 A IL123453 A IL 123453A
- Authority
- IL
- Israel
- Prior art keywords
- chain
- composition
- carbon atoms
- branched
- straight
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19707655A DE19707655A1 (de) | 1997-02-26 | 1997-02-26 | Kombinationspräparat zur Anwendung bei Demenz |
Publications (2)
Publication Number | Publication Date |
---|---|
IL123453A0 IL123453A0 (en) | 1998-09-24 |
IL123453A true IL123453A (en) | 2004-06-20 |
Family
ID=7821517
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL12345398A IL123453A (en) | 1997-02-26 | 1998-02-25 | Pharmaceutical preparation for use in dementia |
Country Status (30)
Country | Link |
---|---|
US (1) | US6037347A (cs) |
EP (1) | EP0867192B1 (cs) |
JP (1) | JP4374440B2 (cs) |
KR (1) | KR100517186B1 (cs) |
CN (1) | CN100363005C (cs) |
AR (1) | AR011860A1 (cs) |
AT (1) | ATE295738T1 (cs) |
AU (1) | AU749278C (cs) |
BR (1) | BR9800766A (cs) |
CA (1) | CA2230350C (cs) |
CZ (1) | CZ298367B6 (cs) |
DE (2) | DE19707655A1 (cs) |
DK (1) | DK0867192T3 (cs) |
EE (1) | EE03387B1 (cs) |
ES (1) | ES2242243T3 (cs) |
HR (1) | HRP980097B1 (cs) |
HU (1) | HUP9800396A3 (cs) |
ID (1) | ID19941A (cs) |
IL (1) | IL123453A (cs) |
MY (1) | MY120530A (cs) |
NO (1) | NO327200B1 (cs) |
NZ (1) | NZ329839A (cs) |
PL (1) | PL191576B1 (cs) |
PT (1) | PT867192E (cs) |
RU (1) | RU2194508C2 (cs) |
SI (1) | SI0867192T1 (cs) |
SK (1) | SK284925B6 (cs) |
TR (1) | TR199800302A3 (cs) |
TW (1) | TW590772B (cs) |
ZA (1) | ZA981561B (cs) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ510683A (en) * | 1998-10-01 | 2003-09-26 | Novartis Ag | Sustained release oral formulations of rivastigmine |
US20040110776A1 (en) * | 2002-02-22 | 2004-06-10 | Iok-Hou Pang | Use of propentofylline to control intraocular pressure |
AU2003270446A1 (en) * | 2002-09-25 | 2004-04-19 | The Board Of Trustees Of The University Of Illinois | Method and composition for treating alzheimer's disease and dementias of vascular origin |
US8481565B2 (en) | 2004-12-27 | 2013-07-09 | Eisai R&D Management Co., Ltd. | Method for stabilizing anti-dementia drug |
US20060280789A1 (en) * | 2004-12-27 | 2006-12-14 | Eisai Research Institute | Sustained release formulations |
US20070129402A1 (en) * | 2004-12-27 | 2007-06-07 | Eisai Research Institute | Sustained release formulations |
US20090208579A1 (en) * | 2004-12-27 | 2009-08-20 | Eisai R & D Management Co., Ltd. | Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same |
WO2006118265A1 (ja) * | 2005-04-28 | 2006-11-09 | Eisai R & D Management Co., Ltd. | 抗痴呆薬を含有する組成物 |
EP4019018A1 (en) | 2015-09-11 | 2022-06-29 | Chase Pharmaceuticals Corporation | Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system |
RU2616247C1 (ru) * | 2016-03-28 | 2017-04-13 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Осетинский государственный университет имени Коста Левановича Хетагурова" (СОГУ) | Твердая лекарственная форма, обладающая холинопозитивным действием, на основе 9-бутиламино-3,3-диметил-1,2,4-тригидроакридина |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3737433A (en) * | 1964-09-05 | 1973-06-05 | Albert Ag Chem Werke | Certain oxoalkyldimethylxanthines |
US3621096A (en) * | 1969-04-03 | 1971-11-16 | Univ North Carolina | Antidepressant method and composition for same comprising a tricyclic antidepressant and a thyroid hormone |
DE2330742C2 (de) * | 1973-06-16 | 1982-07-29 | Hoechst Ag, 6000 Frankfurt | 1-(Oxoalkyl)-3-methyl-7-alkylxanthine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
DE2856393C2 (de) * | 1978-12-27 | 1983-04-28 | Merz + Co GmbH & Co, 6000 Frankfurt | Arzneimittel zur Behandlung von Morbus Parkinson |
JPH062675B2 (ja) * | 1985-04-05 | 1994-01-12 | ヘキストジヤパン株式会社 | 記憶障害治療剤 |
DE3525801A1 (de) * | 1985-07-19 | 1987-01-22 | Hoechst Ag | Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung |
IL81610A (en) * | 1986-02-27 | 1990-12-23 | Roussel Uclaf | Derivatives of 1,2,5,6-tetrahydropyridin-3-carboxaldehyde oxime,their preparation and pharmaceutical compositions containing them |
GB8621870D0 (en) * | 1986-09-11 | 1986-10-15 | Beecham Group Plc | Active compounds |
FI95572C (fi) * | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
IL87861A0 (en) * | 1987-10-05 | 1989-03-31 | Pfizer | 4-aminopyridine derivatives |
WO1989002739A1 (en) * | 1987-10-05 | 1989-04-06 | Pfizer Inc. | 4-aminopyridine derivatives |
DE3817955A1 (de) * | 1988-05-27 | 1989-11-30 | Hoechst Ag | Tnf-inhibitor enthaltendes arzneimittel |
KR920703068A (ko) * | 1989-09-15 | 1992-12-17 | 폴 레이킨드 | 신경변성 질환의 치료방법 |
DE4236331A1 (de) * | 1992-10-28 | 1994-05-05 | Boehringer Ingelheim Kg | Synergistische Kombination |
US5783584A (en) * | 1995-12-11 | 1998-07-21 | Mayo Foundation For Medical Education And Research | THA analogs useful as cholinesterase inhibitors |
GB9612710D0 (en) * | 1996-06-18 | 1996-08-21 | Pfizer Ltd | Method of treatment |
-
1997
- 1997-02-26 DE DE19707655A patent/DE19707655A1/de not_active Withdrawn
-
1998
- 1998-02-16 EP EP98102620A patent/EP0867192B1/de not_active Expired - Lifetime
- 1998-02-16 DK DK98102620T patent/DK0867192T3/da active
- 1998-02-16 DE DE59812801T patent/DE59812801D1/de not_active Expired - Lifetime
- 1998-02-16 ID IDP980209A patent/ID19941A/id unknown
- 1998-02-16 SI SI9830775T patent/SI0867192T1/xx unknown
- 1998-02-16 ES ES98102620T patent/ES2242243T3/es not_active Expired - Lifetime
- 1998-02-16 AT AT98102620T patent/ATE295738T1/de not_active IP Right Cessation
- 1998-02-16 PT PT98102620T patent/PT867192E/pt unknown
- 1998-02-23 EE EE9800075A patent/EE03387B1/xx not_active IP Right Cessation
- 1998-02-24 TR TR1998/00302A patent/TR199800302A3/tr unknown
- 1998-02-24 SK SK240-98A patent/SK284925B6/sk not_active IP Right Cessation
- 1998-02-24 AR ARP980100810A patent/AR011860A1/es not_active Application Discontinuation
- 1998-02-24 TW TW087102577A patent/TW590772B/zh not_active IP Right Cessation
- 1998-02-24 CZ CZ0054098A patent/CZ298367B6/cs not_active IP Right Cessation
- 1998-02-24 AU AU56273/98A patent/AU749278C/en not_active Ceased
- 1998-02-24 NZ NZ329839A patent/NZ329839A/xx unknown
- 1998-02-24 RU RU98103712/14A patent/RU2194508C2/ru not_active IP Right Cessation
- 1998-02-24 CA CA002230350A patent/CA2230350C/en not_active Expired - Fee Related
- 1998-02-25 CN CNB981053289A patent/CN100363005C/zh not_active Expired - Fee Related
- 1998-02-25 IL IL12345398A patent/IL123453A/en not_active IP Right Cessation
- 1998-02-25 HR HR980097A patent/HRP980097B1/xx not_active IP Right Cessation
- 1998-02-25 HU HU9800396A patent/HUP9800396A3/hu unknown
- 1998-02-25 JP JP04305898A patent/JP4374440B2/ja not_active Expired - Fee Related
- 1998-02-25 BR BR9800766-1A patent/BR9800766A/pt not_active Application Discontinuation
- 1998-02-25 MY MYPI98000834A patent/MY120530A/en unknown
- 1998-02-25 ZA ZA981561A patent/ZA981561B/xx unknown
- 1998-02-25 NO NO19980786A patent/NO327200B1/no not_active IP Right Cessation
- 1998-02-25 US US09/030,207 patent/US6037347A/en not_active Expired - Lifetime
- 1998-02-26 PL PL325074A patent/PL191576B1/pl not_active IP Right Cessation
- 1998-02-26 KR KR10-1998-0006051A patent/KR100517186B1/ko not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Schmid et al. | A MAP kinase-signaling pathway mediates neurite outgrowth on L1 and requires Src-dependent endocytosis | |
Kawai et al. | Nicotinic acetylcholine receptors containing α7 subunits on rat cortical neurons do not undergo long‐lasting inactivation even when up‐regulated by chronic nicotine exposure | |
Doerner et al. | Cyclic GMP depresses hippocampal Ca2+ current through a mechanism independent of cGMP-dependent protein kinase | |
US20160082015A1 (en) | Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders | |
CA2230350C (en) | Combination preparation for use in dementia | |
EP1779867A1 (en) | Nerve reveneration promoter | |
WO1996041609A2 (en) | Methods and compositions for stimulating neurite growth | |
WO2010048273A2 (en) | Methods and compounds for treatment of neurodegenerative disorders | |
HRP960372A2 (en) | (1s, 2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanolmethanesulfonate tridydrate | |
AU2005309365B2 (en) | Modulators of muscarinic receptors | |
TW201924676A (zh) | P38激酶抑制劑減少dux4及下游基因表現以供治療fshd | |
US7132287B2 (en) | Method for neural stem cell differentiation using 5HT-1A agonists | |
WO2013024164A1 (en) | Combinations of a 5-ht4 receptor agonist and a pde4 inhibitor for use in therapy | |
US8642612B2 (en) | Nicotinic desensitizers and methods of selecting, testing, and using them | |
WO2012094615A2 (en) | Use of cav3.1 selective t-type calcium channel antagonists | |
Pruss et al. | Cholera toxin stimulates division of 3T3 cells | |
Posern et al. | Rapid lamellipodia formation in nerve growth factor‐stimulated PC12 cells is dependent on Rac and PI3K activity | |
Gagelin et al. | Effects of cyclic AMP on components of the cell cycle machinery regulating DNA synthesis in cultured astrocytes. | |
MXPA98001515A (en) | Prepared combination for application in the demen | |
Calderone et al. | A farnesyltransferase inhibitor attenuates cardiac myocyte hypertrophy and gene expression | |
Lin et al. | 2-Chloroadenosine decreases tyrosylprotein sulfotransferase activity in the Golgi apparatus in PC12 cells. Evidence for a novel receptor | |
Nguyen et al. | Chemical inhibitors of cyclin-dependent kinases control proliferation, apoptosis and differentiation of oligodendroglial cells | |
Diógenes | Cross talk between adenosine A2A receptors and the Trk receptores for brain-derived neurotrophic factor (BDNF) at the rat hippocampus | |
AU6111996A (en) | Methods and compositions for stimulating neurite growth | |
JP2002502355A (ja) | ニューライトの成長を刺激するための方法および組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
MM9K | Patent not in force due to non-payment of renewal fees |